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Abstract
Pyrazinamide is an anti-tubercular agent, used as a part of a three-drug regime (any three of the following: rifampicin,
isoniazid, pyrazinamide, streptomycin or ethambutol) for the initial phase of treatment. One of the effects pyrazinamide has
on mammalian cells is to regulate NAD+/NADH levels. We have recently found that changes in NAD+/NADH are
associated with regulation of expression levels of SUR2A, a cardioprotective protein serving as a regulatory subunit of
cardiac ATP-sensitive K+ (KATP) channels. Here, we have tested whether pyrazinamide regulate expression of SUR2A/KATP
channel subunits and resistance to metabolic stress in embryonic heart-derived H9c2 cells. We have found that 24-h-long
treatment with pyrazinamide (3 mcg/ml) increased mRNA levels of SUR2A, SUR2B and Kir6.1 without affecting mRNA
levels of other KATP channel subunits. This treatment with pyrazinamide (3 mcg/ml) protected H9c2 cells against stress
induced by 10 mM 2,4-dinitrophenol (DNP). The survival rate of DNP-treated cells was 45.6 ± 2.3% (n= 5) if not treated
with pyrazinamide and 90.8 ± 2.3% (n= 5; P < 0.001) if treated with pyrazinamide. We conclude that pyrazinamide
increases resistance to metabolic stress in heart H9c2 cells probably by increasing SUR2A and SUR2B expression. Our
results of this study indicate that pyrazinamide should be seriously considered as a drug of choice for patients with
tuberculosis and ischaemic heart disease.
Pyrazinamide is used as a part of a three-drug regime (three
of rifampicin, isoniazid, pyrazinamide, streptomycin or
ethambutol) for the initial phase of treatment of tuberculosis.
It is unclear how pyrazinamide or its active form, pyrazinoic
acid, induces their bactericidal effect on tubercle bacilli. Two
separate theories have been proposed, the ﬁrst suggests that
pyrazinamide inhibits fatty acid synthase 1 activity to pre-
vent the synthesis of mycolic acid while the second explains
that pyrazinamide reduces the membrane potential of the
bacterial cell wall and prevents transport of nutrients into
Mycobacterium tuberculosis for RNA and protein synthesis.
In mammalian cells, pyrazinamide is known to regulate
intracellular NAD and NADH levels. The drug can either
increase the NAD+ level possibly by inhibiting α-amino-β-
carboxymuconate-ε-semialdehyde dehydrogenase activity
(an enzyme involved in the conversion of tryptophan to
niacin) or decrease the level by potentially blocking the
enzyme required for the biosynthesis of NAD from niacin,
nicotinic acid phosphoribosyltransferase [1].
We have shown that increased NAD+ levels and NAD/
NADH ratio increase intracellular levels of SUR2A, an
ABC protein serving as a regulatory subunit of sarcolemmal
ATP-sensitive K+ (KATP) channels [2–4]. An increase in
intracellular SUR2A level increases levels of fully assem-
bled KATP channels, which, in turn, confers cardioprotection
[5]. On the other hand, a decrease in SUR2A levels results
in increased cardiac susceptibility to metabolic stress [6]. As
pyrazinamide affects NAD and NADH levels, it could
affect the level of SUR2A as well. If it does, it could be
cardioprotective. If it is cardioprotective by regulating
SUR2A, it could be seriously considered as a candidate
drug against heart ischaemia. This is particularly attractive
proposition as upregulation of SUR2A is more and more
viewed as a promising therapeutic strategy against heart
ischaemia. Minimally, if pyrazinamide is cardioprotective,
it could become a drug of choice for TBC patients with
cardiac ischaemia.
Experiments were performed on rat embryonic heart
H9c2 cells (ECACC, Salisbury, UK) cultured at 5% CO2
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containing Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal calf serum (FCS) and 2 mM gluta-
mine. For the experiments H9C2 cells were either treated
with pyrazinamide (3 μg ml−1) and/or vehicle. This parti-
cular concentration of pyrazinamide was selected based on
our preliminary study demonstrating that this is the con-
centration that provides the maximal effect of cytoprotec-
tion. Also, 3 μg ml−1 of pyrazinamide is readily achieved in
the blood when tuberculosis is treated with this drug [7]. As
we have previously shown that mRNA levels of KATP
channel subunits correspond to their protein levels, we have
assessed mRNA levels by real time RT-PCR as we
described earlier [8–10]. Brieﬂy, for each of the primers, an
RT-PCR standard curve (used to test primer efﬁciency) and
a melting curve (used to test primer speciﬁcity) were
obtained. All melting curves for the primers showed a single
peak and the RT-PCR efﬁciency of the primers were:
100.1% for SUR1, 86.1% for SUR2A, 98.0% for SUR2B,
96.5% for Kir6.1, 100.8% for Kir6.2 and 94.5% for creatine
kinase (CK). The relative expression ratio (R) of genes was
calculated using 2−ΔΔCt method [11].
The survival of H9C2 cells were assayed using the
Multitox-Fluor Multiplex Cytotoxicity Assay (Promega).
Brieﬂy, H9C2 cells were plated in complete media
(DMEM containing 10% FCS) in 96-well plates, pyr-
azinamide (3 μg ml−1) or vehicle (controls) was added to the
wells. To induce severe metabolic stress, 2,4-dinitophenol
(DNP), an inhibitor of oxidative phosphorylation was added
to each well at the ﬁnal concentration of 10 mM 24 h later.
Cell survival was measured 6 h later using the peptide
substrate (GF-AFC) that can be cleaved only by live cells.
Following 30-min-long incubation at 37 °C, plates were
measured using 1420 multilabel counter (Victor) plate
reader, with excitation at 370 nm and emissions of 480 nm.
The percentage of live cells was calculated based on the
intensity of ﬂuorescence according to the manufacturer's
instructions [10]. All data are presented as mean ± S.E.M,
with n representing the number of independent experiments.
Mean values were compared by the ANOVA followed by
Student’s t-test or by Student’s t-test alone where appro-
priate using SigmaStat program (Jandel Scientiﬁc, Chicago,
IL). P < 0.05 was considered statistically signiﬁcant.
In previous studies it has been shown that NAD/NADH
ratio might regulate the expression of SUR2A and KATP
channels [2–4]. Therefore, we have measured mRNA levels
of KATP channel subunits in untreated and pyrazinamide (3
μg ml−1) pretreated H9c2 cells using real time RT-PCR.
This method revealed that pre-treatment with pyrazinamide
has signiﬁcantly increased mRNA levels of SUR2A,
SUR2B and Kir6.1 (cycling thresholds: SUR2A: 34.07 ±
0.10 in control cells and 33.58 ± 0.14 in pretreated cells,
n= 6 for each, P= 0.04; SUR2B: 27.60 ± 0.12 in control
cells and 26.97 ± 0.11 in pretreated cells, n= 6 for each,
P < 0.01; Kir6.1: 25.78 ± 0.07 in control cells and 25.13 ±
0.06 in pretreated cells, n= 6 for each, P < 0.01; Fig. 1). An
increase in mRNA levels was calculated to be 41.7 ± 10.6%
(n= 6) for SUR2A, 55.2 ± 2.3% (n= 6) for SUR2B and
57.3 ± 4.7% (n= 6) for Kir6.1 (Fig. 1).
No statistically signiﬁcant difference was observed in
mRNA levels of SUR1 and Kir6.2 as well as CK (cycling
thresholds: SUR1: 31.92 ± 0.07 in control cells and 31.75 ±
0.05 in pretreated cells, n= 6 for each, P= 0.34; Kir6.2:
30.58 ± 0.20 in control cells and 30.23 ± 0.20 in pretreated
cells, n= 6 for each, P= 0.54; CK: 31.40 ± 0.26 in control
cells and 31.13 ± 0.43 in pretreated cells, n= 6 for each,
P= 0.53; Fig. 1) (Fig. 1).
DNP is a known metabolic inhibitor that is used to
induce metabolic stress in different cell types. When control
cells were treated with DNP (10 mM), only 45.6 ± 2.3%
(n= 5) of cells have survived this insult (Fig. 2). Cells
C
t
20
24
28
32
36 Control
Pyrazinamide
*
*
SUR1
SUR2A
SUR2B
Kir6.1
Kir6.2
*
CK
m
R
N
A
 le
ve
l i
nc
re
as
e 
(%
)
0
10
20
30
40
50
60
70
SUR2A SUR2B Kir6.1
Fig. 1 Pyrazinamide upregulates
SUR2A, SUR2B and Kir6.1 in
H9c2 cells. Bar graph represents
cycling thresholds (Ct) of the
real time RT-PCR progress
curves of KATP channel subunits
and creatine kinase (CK) as
labelled in control cells and cells
cultured with pyrazinamide
(3 μg ml−1). Each bar represent
mean ± SEM (n= 6 for each).
*P < 0.05 when compared to
control. Smaller graph represent
an increase in mRNA levels
calculated for KATP channel
subunits with signiﬁcantly
different Ct values. Each bar
represent mean ± SEM (n= 6
for each)
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pretreated with pyrenzamide (3 μg ml−1) were signiﬁcantly
more resistant to DNP (10 mM) than control cells (90.8 ±
1.5% of cells pretreated with pyrazinamide have survived
DNP, n= 5, P < 0.001 when compared to the control,
Fig. 2).
Pyrazinamide is a drug standardly used to treat tuber-
culosis as a part of a three-drug regime. It has been pre-
viously shown that in mammalian cells this antituberculotic
affects levels of NAD/NADH. It has been previously
demonstrated that changes in ratio of NAD/NADH reg-
ulates the level of SUR2A and, consequently, cardiac
resistance to different types of metabolic stresses, including
ischaemia-reperfusion [2–4]. Here, we have assessed whe-
ther pyrazinamide, that reportedly regulates NAD/NADH
ratio [12, 13], would affect the level of SUR2A. We have
found that this drug speciﬁcally increases SUR2A, SUR2B
and Kir6.1 without affecting other KATP channel subunits.
Previously it has been shown that increase in NAD+ con-
centration in vitro increases SUR2A expression which is
sufﬁcient to increase the number of fully assembled KATP
channel subunits [2–4]. It has been suggested that the level
of SUR2A is the rate-limiting step in formation of fully
assembled KATP channels as it seems that this subunit is the
least expressed of all KATP channel subunits [8]. In the
present study, SUR2A expression was also increased, but,
as opposed to previous studies, SUR2B and Kir6.1 were
also upregulated. Whether this increase in mRNA levels of
three channel subunits would result in increased resistance
to metabolic stress was not clear at that point. SUR2A binds
to inward rectiﬁers Kir6.2 and Kir6.1 to form cardiac sar-
colemmal KATP channels [14]. Increased level of SUR2A in
the heart protects myocardium against ischaemia-
reperfusion and protects cardiomyocytes against different
types of metabolic stresses [15–17]. However, it was not
clear what effect on cellular resistance to stress would result
when SUR2A is not increased individually, but also in
combination with increase in Kir6.1 and SUR2B. It has
been previously shown that concomitant overexpression of
SUR2A/Kir6.2 offers less cytoprotection than over-
expression of SUR2A alone [9]. On the other hand, an
increase in SUR2B levels in H9c2 cells has been demon-
strated to be cytoprotective [18]. DNP is a known metabolic
inhibitor that was used in many studies to induce metabolic
stress in different cell types [17, 18]. When applied, this
compound inhibits oxidative phosphorylation resulting in
decreased ATP production inducing severe metabolic stress.
It has been previously shown that increased SUR2A and
SUR2B each protect H9c2 cells against DNP-induced
metabolic stress [9, 17]. We did not measure protein levels
of SUR2A and other channel subunits ion this occasion as
all studies done so far have demonstrated that changes in
mRNA levels are followed up by corresponding changes in
protein levels [2–4, 8, 10]. In addition, it has been shown
that therapeutic strategies protecting against DNP-induced
chemical hypoxia, without any exceptions reported so far,
are also successful in protecting myocardium against
ischaemia-reperfusion [2–4, 8, 10, 19]. It should be pointed
out that the level of protection of H9c2 cells from DNP-
induced stress is much higher than the level of over-
expression of SUR2A alone [10]. It is possible that
concomitant upregulation of SUR2B or even Kir6.1 con-
tribute to cytoprotection afforded by pyrazinamide.
This is the ﬁrst report ever to suggest that pyrazinamide
is cardioprotective. Monocyte/macrophages, lymphocytes
and cytokines involved in cellular-mediated immune
responses against M. tuberculosis are also main drivers of
atherogenesis [20]. Tuberculous granuloma formation
affecting the coronary arteries has been described as a cause
of myocardial infarction in some patients [21] and an
increased risk of acute myocardial infarction in patients
with tuberculosis has been reported [22]. Taken all together,
cardioprotective properties of pyrazinamide should be
considered when evaluating place of this drug in therapy of
tuberculosis. Pyrazinamide would be obvious choice for
treating patients with tuberculosis and ischaemic heart
disease.
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Fig. 2 Pyrazinamide protects H9c2 cells against DNP. Bar graph
showing a percentage of survival in cells cultured without and with
3 μg ml−1 pyrazinamide exposed to DNP (10 mM). Each bar represent
mean ± SEM (n= 5 for each)
Pyrazinamide may possess cardioprotective properties
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Stehr M, Elamin AA, Singh M. Pyrazinamide: the importance of
uncovering the mechanisms of action in mycobacteria. Expert Rev
Anti Infect Ther 2015;13:593–693.
2. Crawford RM, Jovanović S, Budas GR, Davies AM, Lad H,
Wenger RH, Robertson KA, Roy DJ, Ranki HJ, Jovanović A.
Chronic mild hypoxia protects heart-derived H9c2 cells against
acute hypoxia/reoxygenation by regulating expression of the
SUR2A subunit of the ATP-sensitive K+ channels. J Biol Chem
2003;278:31444–55.
3. Sukhodub A, Du Q, Jovanović S, Jovanović A. Nicotinamide-rich
diet protects the heart against ischaemia-reperfusion in mice: a
crucial role for cardiac SUR2A. Pharm Res. 2010;61:564–70.
4. Sukhodub A, Sudhir R, Du Q, Jovanović S, Reyes S, Jovanović
A. Nicotinamide-rich diet improves physical endurance by upre-
gulating SUR2A in the heart. J Cell Mol Med 2011;15:1703–12.
5. Jovanović A. Cardioprotective signalling: past, present and future.
Eur J Pharm. 2018;833:314–9.
6. Du Q, Jovanovi S, Sukhodub A, Ngoi YS, Lal A, Zheleva M,
Jovanović A. Insulin down-regulates cardioprotective SUR2A in the
heart-derived H9c2 cells: a possible explanation for some adverse
effects of insulin therapy. Biochem Biophys Rep 2018;16:12–8.
7. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H,
Ascobat P, Donders R, van Crevel R, Aarnoutse R. Isoniazid,
rifampin, and pyrazinamide plasma concentrations in relation to
treatment response in Indonesian pulmonary tuberculosis patients.
Antimicrob Agents Chemother. 2013;57:3614–9.
8. Du Q, Jovanović S, Clelland A, Sukhodub A, Budas GR, Phelan
K, Murray-Tait V, Malone L, Jovanović A. Overexpression of
SUR2A generates a cardiac phenotype resistant to ischaemia.
FASEB J. 2006;20:1131–41.
9. Ballantyne T, Du Q, Jovanović S, Neemo A, Holmes R, Sinha S,
Jovanović A. Testosterone protects female embryonic heart H9C2
cells against severe metabolic stress by activating estrogen
receptors and up-regulating IES SUR2B. Int J Biochem Cell Biol.
2013;45:283–91.
10. Du Q, S. Jovanović S, Sukhodub A, JovanovićA. Infection with AV-
SUR2A protects H9C2 cells against metabolic stress: a mechanism of
SUR2A-mediated cytoprotection independent from the KATP chan-
nels activity. Biochim Biophys Acta 2010;1803:405–15.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression
data using real-time quantitative PCR and the 2−ΔΔCT method.
Methods 2001;25:402–8.
12. Shibata K, Fukuwatari T, Sugimoto E. Effects of dietary pyr-
azinamide, an antituberculosis agent, on the metabolism of tryp-
tophan to niacin and of tryptophan to serotonin in rats. Biosci
Biotechnol Biochem. 2001;65:1339–46.
13. Bhat SA, Iqbal IK, Kumar A. Imaging the NADH:NAD+
homeostasis for understanding the metabolic response of myco-
bacterium to physiologically relevant stresses. Front Cell Infect
Microbiol 2016;6:145.
14. Tinker A, Aziz Q, Li Y, Specterman M. ATP-sensitive potassium
channels and their physiological and pathophysiological roles.
Compr Physiol 2018;8:1463–511.
15. Mohammed Abdul KS, Jovanović S, Du Q, Sukhodub A, Jovanović
A. Upregulation of cardioprotective SUR2A by sub-hypoxic drop in
oxygen. Biochim Biophys Acta 2014;1843:2424–31.
16. Jovanović S, Jovanović N, Jovanović A. High glucose protects
single beating adult cardiomyocytes against hypoxia. Biochem
Biophys Res Commun. 2006;341:57–66.
17. Jovanović S, Du Q, Sukhodub A, Jovanović A. Dual mechanism
of cytoprotection afforded by M-LDH in embryonic heart H9C2
cells. Biochim Biophys Acta 2009;1793:1379–86.
18. Jovanović S, Ballantyne T, Du Q, Blagojević M, Jovanović A.
Phenylephrine preconditioning in embryonic heart H9c2 cells is
mediated by up-regulation of SUR2B/Kir6.2: a ﬁrst evidence for
functional role of SUR2B in sarcolemmal KATP channels and
cardioprotection. Int J Biochem Cell Biol. 2016;70:23–8.
19. Jovanović S, Jovanović A, Shen WK, Terzic A. Low concentra-
tions of 17β-estradiol protect single cardiac cells against hypoxia-
reoxygenation induced Ca2+ loading. J Am Coll Cardiol. 2000;
36:948–52.
20. Huaman MA, Henson D, Ticona E, Sterling TR, Garvy BA.
Tuberculosis and cardiovascular disease: linking the epidemics.
Trop Dis Travel Med Vaccin 2015;1:10.
21. Rodriguez Y, de Armas Y, Capo V, Wissmann G, Goldani LZ, De
Waard JH. Sudden death related to tuberculous coronary arteritis.
Int J Cardiol. 2012;156:e28–9.
22. Huaman MA, Kryscio RJ, Fichtenbaum CJ, Henson D, Salt E,
Garvy BA. Tuberculosis and risk of acute myocardial infarction: a
propensity score-matched analysis. Epidemiol Infect 2017;145:
1363–7.
S. Sinha et al.
